Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma.

Wentink MQ, Verheul HMW, Pal SK, George S, Voortman J, Danchaivijitr P, Adelaiye R, Poslinski D, Groman A, Hutson A, Pili R.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30201-X. doi: 10.1016/j.clgc.2017.07.004. [Epub ahead of print]

PMID:
28781191
2.

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.

Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, Carducci MA.

Br J Cancer. 2017 Mar 28;116(7):874-883. doi: 10.1038/bjc.2017.33. Epub 2017 Feb 21.

3.

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.

Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G, Pili R.

Oncogene. 2016 Mar 24;35(12):1541-53. doi: 10.1038/onc.2015.219. Epub 2015 Jun 29.

4.

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature.

Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM.

Oncoscience. 2014 Dec 15;1(12):844-53. eCollection 2014.

5.

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, Bjarnason GA, Pili R.

Mol Cancer Ther. 2015 Feb;14(2):513-22. doi: 10.1158/1535-7163.MCT-14-0208. Epub 2014 Dec 17.

6.

Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.

Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R.

PLoS One. 2014 Nov 13;9(11):e112371. doi: 10.1371/journal.pone.0112371. eCollection 2014.

7.

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.

Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R.

Mol Cancer Ther. 2015 Jan;14(1):101-10. doi: 10.1158/1535-7163.MCT-14-0094. Epub 2014 Nov 7.

8.

Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.

Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, Pili R.

Cancer Immunol Res. 2015 Feb;3(2):136-48. doi: 10.1158/2326-6066.CIR-14-0036. Epub 2014 Nov 4.

9.

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.

Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R.

PLoS One. 2014 Jul 29;9(7):e103680. doi: 10.1371/journal.pone.0103680. eCollection 2014.

10.

Dietary protein restriction inhibits tumor growth in human xenograft models.

Fontana L, Adelaiye RM, Rastelli AL, Miles KM, Ciamporcero E, Longo VD, Nguyen H, Vessella R, Pili R.

Oncotarget. 2013 Dec;4(12):2451-61.

11.

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.

Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R.

PLoS One. 2011;6(11):e27178. doi: 10.1371/journal.pone.0027178. Epub 2011 Nov 7.

12.

Development of a castrate resistant transplant tumor model of prostate cancer.

Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R.

Prostate. 2012 May 1;72(6):587-91. doi: 10.1002/pros.21465. Epub 2011 Jul 27.

13.

Awareness and knowledge of ocular cancers in a resource-limited economy.

Ayanniyi AA, Jamda AM, Badmos KB, Adelaiye RS, Mahmoud AO, Kyari F, Nwana EJ.

N Am J Med Sci. 2010 Nov;2(11):526-31. doi: 10.4297/najms.2010.2526.

14.

Knowledge and attitudes towards cervical cancer and human papillomavirus: a Nigerian pilot study.

Nnodu O, Erinosho L, Jamda M, Olaniyi O, Adelaiye R, Lawson L, Odedina F, Shuaibu F, Odumuh T, Isu N, Imam H, Owolabi O, Yaqub N, Zamani A.

Afr J Reprod Health. 2010 Mar;14(1):95-108.

PMID:
20695142

Supplemental Content

Loading ...
Support Center